Singapore BIOPHARMA PTE. LTD. officially announces the acquisition of exclusive distribution rights for BARHEMSYS® (amisulpride) injection in Singapore.
BARHEMSYS® is an intravenous amisulpride injection specifically designed for timely and aggressive treatment of breakthrough postoperative nausea and vomiting (PONV) in patients. This product provides perioperative healthcare professionals with an effective PONV management solution.